IMAX Insider Weissman Exercises 7,072 Options, Sells Shares at ~$25.63
Rhea-AI Filing Summary
Kenneth Ian Weissman, IMAX Corp executive (Deputy General Counsel, Corporate Secretary & Chief Compliance Officer), reported option exercise and subsequent share sales on 08/14/2025. He exercised 7,072 stock options with an exercise price of $22.49 (options issued in 2019, expiring 03/07/2026) converting them into 7,072 common shares. The filing shows two dispositions the same day: sale of 7,072 shares at $25.6707 and sale of 8,000 shares at $25.6272.
Ownership changed from an opening balance of 34,133 common shares to a post-transaction balance of 26,133 common shares. The filing notes Mr. Weissman retains 17,021 restricted share units outstanding and that the exercised options were vested in installments between 2020 and 2023.
Positive
- Options exercised at $22.49 and sold at higher prices (~$25.63–$25.67), indicating a realized gain before taxes and fees
- Clear disclosure of vesting schedule and option expiration (03/07/2026) improves transparency for investors
Negative
- Net reduction in common shares from 34,133 to 26,133, representing decreased insider ownership in absolute terms
- No explicit 10b5-1 plan referenced in the filing, so sales appear to be discretionary rather than under a pre-established trading plan
Insights
TL;DR: Routine option exercise followed by same-day sales; small net reduction in holdings, consistent with typical executive liquidity actions.
The report documents conversion of 7,072 options at a $22.49 exercise price and immediate sales at roughly $25.63–$25.67, implying a per-share spread realized before fees and taxes. The transactions appear non-controversial and do not indicate new compensation terms or extraordinary transfers. Remaining common shares total 26,133 with 17,021 RSUs outstanding, leaving material ownership intact relative to routine insider activity.
TL;DR: Disclosure follows Rule 16 reporting norms; vesting schedule and option expiry are clearly stated.
The Form 4 discloses exercisable option tranches (1,414; 1,768; 1,768; 2,122) and the 03/07/2026 expiration, which helps trace long-term incentive timing. Sales executed the same day as exercise may reflect pre-arranged liquidity or tax-driven decisions; the filing does not state a 10b5-1 plan. No departures, grants, or other governance events are reported.
Insider Trade Summary
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Conversion | stock options (to buy) | 7,072 | $22.49 | $159K |
| Conversion | common shares | 7,072 | $22.49 | $159K |
| Sale | common shares | 7,072 | $25.6707 | $182K |
| Sale | common shares | 8,000 | $25.6272 | $205K |
| holding | common shares (opening balance) | -- | -- | -- |
Footnotes (1)
- Represents the conversion upon exercise of stock options into common shares. These options were issued in 2019 and are set to expire on March 7, 2026. The stock options became exercisable in four installments: 1,414 on March 7, 2020, 1,768 on each of March 7, 2021 and March 7, 2022, and 2,122 on March 7, 2023. This represents the number of restricted share units for this transaction only. Mr. Weissman's aggregate remaining outstanding restricted share unit and common share balances following these transactions will be 17,021 and 26,133. respectively.
